Deutsche Bank Raises Sarepta Therapeutics' Price Target to $12.00 While Maintaining Sell Rating

Deutsche Bank analyst David Hoang raised Sarepta Therapeutics (SRPT) price target from $6.00 to $12.00 while maintaining a "Sell" rating. This represents a 100% increase in the target price. Other analysts have also weighed in with various ratings and price targets, including Goldman Sachs, Wells Fargo, Barclays, and Bernstein. The average one-year target price for SRPT is $32.65, with an average brokerage recommendation of 2.8, indicating a "Hold" status.

Sarepta Therapeutics, Inc. (SRPT) has seen a significant shift in analyst sentiment and price targets following recent financial developments. The company announced the sale of 9.3 million shares of Arrowhead Pharmaceuticals, Inc. (ARWR) in a privately negotiated block trade, aiming to raise at least $174 million [1]. This move aligns with Sarepta's broader financial strategy to address its financial challenges and fulfill obligations related to the SRP-1003 trial for type 1 myotonic dystrophy (DM1) [1].

Deutsche Bank analyst David Hoang recently raised Sarepta's price target from $6.00 to $12.00, while maintaining a "Sell" rating. This represents a 100% increase in the target price [2]. Other analysts have also weighed in with various ratings and price targets. Goldman Sachs, Wells Fargo, Barclays, and Bernstein have all provided their assessments, with the average one-year target price for SRPT standing at $32.65, indicating a "Hold" status [2].

The average brokerage recommendation of 2.8 suggests a cautious approach, with analysts noting the potential risks associated with Sarepta's financial strategy and ongoing trials. The company's commitment to its research and development initiatives, particularly in the genetic disorder space, is evident in its planned sharing of early results from the SRP-1003 trial and its facioscapulohumeral muscular dystrophy (FSHD) program in the second half of 2025 [1].

The biotech sector continues to see significant activity, with other notable developments including advancements in mRNA technology, discussions surrounding Medicare policies, and strategic moves by major pharmaceutical firms such as Merck [1]. These developments highlight ongoing shifts and decisions shaping the biotech landscape.

References:
[1] https://www.ainvest.com/news/sarepta-therapeutics-raises-174-million-selling-arrowhead-pharmaceuticals-shares-analysts-predict-significant-upside-stock-price-2508/
[2] https://www.marketscreener.com/news/sarepta-therapeutics-still-faces-elevidys-demand-uncertainty-deutsche-bank-says-ce7c51dede8bf622